Bicara Therapeutics Inc. Common Stock (BCAX) vs Damora Therapeutics, Inc. (DMRA)

A side-by-side comparison of Bicara Therapeutics Inc. Common Stock and Damora Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Bicara Therapeutics Inc. Common Stock logo
BCAX
Bicara Therapeutics Inc. Common Stock
$1.12B
$17.05HealthcareDelayed quote: Oct 6, 2026, 10:05 AM EDT
Damora Therapeutics, Inc. logo
DMRA
Damora Therapeutics, Inc.
$1.19B
$19.27HealthcareDelayed quote: Oct 6, 2026, 10:05 AM EDT

Total return — BCAX vs DMRA

growth of $100 · dividends reinvested · last 2y
BCAX -26.1% (-14.1%/yr)DMRA +42.9% (+19.5%/yr)DMRA compounded faster over this window
050100150200250Start $10020252026$74$143
BCAX DMRA

BCAX vs DMRA: by the numbers

  • •DMRA is the larger company ($1.19B vs $1.12B market cap).

Metrics side by side

Valuation

MetricBCAXDMRA
P/B ratio2.393.07

Profitability

MetricBCAXDMRA
Gross margin0.00%0.00%
Operating margin0.00%0.00%
Net margin0.00%0.00%
ROE-39.54%-50.93%
ROIC-42.98%-52.44%

Growth (annualized)

MetricBCAXDMRA
Total return CAGR (5Y)N/A-25.05%

Go deeper

Full BCAX analysisFull DMRA analysisInteractive comparison tool

Dig into the metrics

Bicara Therapeutics Inc. Common Stock ROEDamora Therapeutics ROEBicara Therapeutics Inc. Common Stock operating marginDamora Therapeutics operating marginBicara Therapeutics Inc. Common Stock revenue growthDamora Therapeutics revenue growthBicara Therapeutics Inc. Common Stock free cash flowDamora Therapeutics free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.